Health Care & Life Sciences » Pharmaceuticals | Immune Design Corp.

Immune Design Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
15,975.00
34,151.00
39,445.00
53,530.00
51,862.00
Depreciation, Depletion & Amortization
407.00
238.00
243.00
304.00
351.00
Other Funds
2,381.00
-
-
-
-
Funds from Operations
14,264.00
28,292.00
32,905.00
43,817.00
42,904.00
Changes in Working Capital
34.00
7,623.00
4,896.00
8,077.00
4,155.00
Net Operating Cash Flow
14,298.00
20,669.00
37,801.00
35,740.00
47,059.00
Capital Expenditures
175.00
344.00
427.00
133.00
428.00
Sale of Fixed Assets & Businesses
43.00
-
-
-
-
Purchase/Sale of Investments
-
-
-
62,288.00
6,611.00
Net Investing Cash Flow
132.00
344.00
427.00
62,421.00
7,039.00
Net Financing Cash Flow
32,055.00
65,980.00
75,795.00
30,454.00
87,338.00
Net Change in Cash
17,625.00
44,967.00
37,567.00
67,707.00
33,240.00
Free Cash Flow
14,473.00
21,013.00
38,228.00
35,873.00
47,487.00
Change in Capital Stock
29,674.00
65,980.00
75,795.00
30,454.00
87,338.00

About Immune Design

View Profile
Address
1616 Eastlake Avenue East
Seattle Washington 98102
United States
Employees -
Website http://www.immunedesign.com
Updated 09/14/2018
Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G.